Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Guillermo Tearney

Massachusetts General Hospital, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

SpectraWave

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Tearney is a co-founder and Board Member of SpectraWave, a start-up company focused on developing an OCT-NIRS intracoronary imaging system and catheter invented by Dr. Tearney. This research project will develop a new intracoronary imaging catheter that rapidly measures the force of flowing blood on endothelial cells that causes atherosclerotic plaque progression. Therefore, the results of the research may be of interest to SpectraWave. The institution determined that, given the magnitude of the financial interest in addition to the close connection between the aims of the company’s interests and the aims of the research, Dr. Tearney’s financial interest could directly and significantly affect the design, conduct, or reporting of the research.

Listed Research Project
Unique value of real-time shear stress to enhance coronary disease management

Project Narrative In this proposal, we will develop a new intracoronary imaging catheter that rapidly measures the force of flowing blood on endothelial cells that causes atherosclerotic plaque progression and leads to cardiac chest pains (angina) and heart attacks. By enabling this parameter to be measured in the cardiac catheterization lab, this device will allow cardiologists to more accurately diagnose and treat plaques that will cause events, resulting in improved patient outcomes.

Filed on January 02, 2018.

Tell us what you know about Guillermo Tearney's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page